Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0520
Trial ID NCT04314843
Disease Large B-Cell Lymphoma
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment Axi-Cel|Relma-cel|Axicabtagene Ciloleucel|JWCAR029|relmacabtagene autoleucel|Yescarta
Co-treatment Lenzilumab
Location approved China
PhasePhase1
Recruitment statusTerminated
TitleA Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)
Year2020
CountryUnited States
Company sponsorKite, A Gilead Company
Other ID(s)KT-US-471-0119|2019-004568-23

Clinical Result

Cohort1: 600 mg lenzilumab
Administration route intravenous infusion
Donor type autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Adverse reactions 2/3(All-cause mortality); 2/3(Blood and lymphatic system disorders; Infections and infestations; Metabolism and nutrition disorders; Nervous system disorders; Vascular disorders)
Cohort2: 1800 mg lenzilumab
Administration route intravenous infusion
Donor type autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Adverse reactions 2/3(All-cause mortality); 3/3(General disorders; Musculoskeletal and connective tissue disorders; Nervous system disorders; Psychiatric disorders)

Relationship Graph

Overview of Knowledge Graph